Anocca AB, a leader in unlocking the potential of T cell immunotherapy to deliver transformative T cell receptor engineered T cell therapeutics (TCR-T), today announced it has appointed a new Head of Clinical Development, Sandra Bevan MSc.
Södertälje, Sweden, 9 November 2021 – Anocca AB, a leader in unlocking the potential of T cell immunotherapy to deliver transformative T cell receptor engineered T cell therapeutics (TCR-T), today announced it has appointed a new Head of Clinical Development, Sandra Bevan MSc.
Sandra brings 25 years’ experience in strategic and operational global drug development from Pharmaceutical and Biotech companies. Sandra served 17 years at AstraZeneca in global clinical development and cross-functional project management positions. For the past 8 years she has been the owner and Senior Pharmaceutical Development Consultant at Bevan Consulting AB. One of her core strengths is building and leading clinical teams, in all phases of clinical development. Sandra received her MSc in Health Sciences from The University of York, UK. Prior to joining the industry, she worked as a Registered Nurse in the UK’s NHS.
Anocca’s CEO and co-founder Reagan Jarvis, said, “We’re delighted that Sandra has joined us as our Head of Clinical Development, as we focus on moving our unique approach to generating novel TCR-T therapeutics towards the clinic.”
Anocca’s Head of Clinical Development, Sandra Bevan, said, “It is a real pleasure and an inspiring opportunity to join Anocca, and I’m looking forward to using my experience to take Anocca’s unique innovative approach to deciphering T cell immunity towards clinical development.”
- Ends -
Media contacts:
Anocca
Vice President Business Development
Mark Farmery
+46766474942
Scius Communications (for international media)
Katja Stout
+447789435990
Daniel Gooch
+447747875479
daniel@sciuscommunications.com
Cord Communications (for Swedish and Nordic media)
Mikael Widell
+46 703 11 99 60
About Anocca
Anocca is leveraging its highly scalable precision analysis technologies to develop transformative TCR-T immunotherapies to treat cancer and other serious diseases. The company has pioneered a proprietary industrialised analytical cell biology platform that enables a deep understanding of disease specific T cell biology to deliver highly targeted cell-based therapies. The company’s innovative ‘engineered immunity’ approach to deciphering T cell immunity can reach an unprecedented number of druggable targets in oncology and other therapeutic areas, such as infectious diseases and autoimmune disorders. Anocca has a fully integrated R&D infrastructure, with a range of scalable analytics platforms leveraging extensive libraries of engineered cells and complemented by a clinical manufacturing and process development facility. The company’s platform has generated a broad pipeline of blockbuster assets focusing on distinct disease franchises. The company expects to progress several TCR-T therapies to the clinic.
Anocca was founded in 2014 and is led by an experienced management team that has raised over USD 100 million in funding from leading Nordic investors Swedbank Robur Ny Teknik, Ramsbury Invest, Mellby Gård, Nidoco and Michano with Danske Bank acting as advisor. Anocca’s team of over 70 employees operates from its site in Södertälje, Sweden. To learn more about Anocca, please visit www.anocca.com and follow our LinkedIn.
